Contemporary use of guideline‐based higher potency P2Y12 receptor inhibitor therapy in patients with moderate‐to‐high risk non‐ST‐segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross‐sectional study
| العنوان: | Contemporary use of guideline‐based higher potency P2Y12 receptor inhibitor therapy in patients with moderate‐to‐high risk non‐ST‐segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross‐sectional study |
|---|---|
| المؤلفون: | Patel, Ashish, Goodman, Shaun G., Tan, Mary, Suskin, Neville, McKelvie, Robert, Mathew, Andrew L., Lutchmedial, Sohrab, Dehghani, Payam, Lavoie, Andrea J., Huynh, Thao, Lavi, Shahar, Philipp, Roger, Khan, Razi, Yan, Andrew T., Radhakrishnan, Sam, Sedlak, Tara, Brunner, Nathan, Kim, Hahn Hoe, Cieza, Tomas, Kassam, Saleem, Fordyce, Christopher B., Heffernan, Michael, Jedrzkiewicz, Sean, Madan, Mina, Ahmed, Shaheeda, Barry, Colin, Dery, Jean‐Pierre, Bagai, Akshay |
| المصدر: | Clinical Cardiology |
| بيانات النشر: | Wiley Periodicals, Inc., 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Canada, Ticlopidine, Clinical Investigations, Myocardial Infarction, acute coronary syndrome, Cross-Sectional Studies, Percutaneous Coronary Intervention, Treatment Outcome, Purinergic P2Y Receptor Antagonists, Humans, Prospective Studies, pharmacology, Non-ST Elevated Myocardial Infarction, Prasugrel Hydrochloride, Platelet Aggregation Inhibitors |
| الوصف: | Background After myocardial infarction, guidelines recommend higher‐potency P2Y12 receptor inhibitors, namely ticagrelor and prasugrel, over clopidogrel. Hypothesis We aimed to determine the contemporary use of higher‐potency antiplatelet therapy in Canadian patients with non‐ST‐elevation myocardial infarction (NSTEMI). Methods A total of 684 moderate‐to‐high risk NSTEMI patients were enrolled in the prospective Canadian ACS Reflective II registry at 12 Canadian hospitals and three clinics in five provinces between July 2016 and May 2018. Multivariable logistic regression modeling was performed to assess factors independently associated with higher‐potency P2Y12 receptor inhibitor use at discharge. Results At hospital discharge, 78.3% of patients were treated with a P2Y12 receptor inhibitor. Among patients discharged on a P2Y12 receptor inhibitor, use of higher‐potency P2Y12 receptor inhibitor was 61.4%. After adjustment, treatment in‐hospital with PCI (OR 4.48, 95%CI 3.34–6.03, p |
| اللغة: | English |
| تدمد: | 1932-8737 0160-9289 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=pmid________::b3dc46e198193647c70fded926687707Test http://europepmc.org/articles/PMC8207978Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.pmid..........b3dc46e198193647c70fded926687707 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19328737 01609289 |
|---|